Genoox

Genoox is a healthcare and technology company aiming to make clinical genetic sequencing more accessible. Using the companys cloud-based advanced framework encompassing purpose-built applications, users can easily manage the entire genetic sequencing process and create virtual genetic test modules providing plug-and-play options for the delivery of clinical actionable insights and disease diagnoses. Driven by artificial intelligence technology, the companys product, Franklin, integrates data from published literature and publicly available population, disease, and sequence databases and employs machine learning to derive a prediction aggregation score and adjust the weights of ACMG classification criteria. Genoox removes the final barrier to widespread adoption of clinical NGS, enabling personalized medicine for mainstream patients. Its platform is used in the diagnosis and treatment of genetic disorders and cancer, as well as new drug discovery and family planning. Genoox aims to improve patient outcomes with increased accuracy and efficiency, enabling personalized medicine and patient-specific treatments.

Genoox has raised $20M in total funding across 6 rounds. The company is currently at the Acquired stage. Key investors include Artofin, IN Venture, Inimiti.

Genoox was founded in 2014 by Moshe Einhorn (Co-founder & CTO).

Genoox operates in Health Tech & Life Sciences, Digital Healthcare, Medical Decision Support, with core technologies in Artificial Intelligence, Machine Learning, Data Storage, Cloud, Platforms & Interfaces, Software. Target customers: Healthcare & Life Sciences, Healthcare, Providers, Life Sciences, Pharmaceuticals.

Genoox is based in Tel Aviv-Yafo, Israel, Center District. The company also has offices abroad.